Tocilizumab for Relapsing Polychondritis

Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01104480

Enrollment

Registered

2010-04-15

Start date

2010-05-31

Completion date

2012-05-31

Last updated

2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing Polychondritis

Keywords

Relapsing Polychondritis, Unremitting, Inflammation, IL6

Brief summary

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Interventions

DRUGTocilizumab

Tocilizumab 8mg/kg every 2 weeks given by IV infusion

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

12 Years to 15 Years

Healthy volunteers

Inclusion criteria

* A single patient with unremitting inflammatory relapsing polychondritis

Exclusion criteria

* As this is a study in a single patient, there are no exclusions

Design outcomes

Primary

Measure	Time frame	Description
Efficacy of Tocilizumab	2 years	Inhibition of inflammatory markers Improvement in symptoms and signs

Secondary

Measure	Time frame	Description
Safety of Tocilizumab	2 years	Monitoring of serum lipids and liver function tests

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026